Identifying prognostic gene panels in acute myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute Myeloid Leukemia (AML) is a complex blood cancer with diverse genetic profiles impacting prognosis and treatment.
• Accurate genetic subtyping is essential for effective clinical management and targeted therapy selection in AML.

Approach:

• This review synthesizes current knowledge on prognostic gene mutations in AML, referencing the European LeukemiaNet (ELN) risk classification.
• It highlights the utility of various molecular techniques, including quantitative reverse transcription PCR (qRTPCR), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) panels.

Key Points:

• NPM1 mutations and CBF rearrangements identify favorable prognosis in younger AML patients, enabling measurable residual disease-guided chemotherapy.
• Rapid detection of FLT3-ITD mutations is critical for initiating targeted therapies like midostaurin or quizartinib, assigning intermediate prognosis.
• Conventional cytogenetics and FISH detect adverse risk karyotypes and specific gene rearrangements (KMT2A, MECOM, NUP98).
• NGS panels further characterize favorable (e.g., CEBPA bZIP) and adverse prognosis genes (e.g., TP53, myelodysplasia-associated genes).

Conclusions:

• Efficient genetic abnormality detection is a necessary tool in routine AML clinical practice.
• Tailoring AML treatment based on precise genetic findings significantly improves patient stratification and therapeutic strategies.